O	0	5	Tumor
O	6	13	factors
O	14	24	predictive
O	25	27	of
O	28	36	response
O	37	39	to
B-intervention	40	56	hypofractionated
I-intervention	57	69	radiotherapy
O	70	72	in
O	73	74	a
O	75	85	randomized
O	86	91	trial
O	92	101	following
O	102	108	breast
O	109	119	conserving
O	120	127	therapy
O	127	128	.

O	129	131	To
O	132	141	determine
O	142	149	whether
O	150	155	tumor
O	156	161	grade
O	161	162	,
O	163	172	molecular
O	173	180	subtype
O	181	184	and
O	185	192	hypoxia
O	193	200	predict
O	201	209	response
O	210	212	to
O	213	229	hypofractionated
O	230	236	versus
B-control	237	245	standard
I-control	246	258	radiotherapy
I-control	259	260	(
I-control	260	262	RT
I-control	262	263	)
O	264	273	following
O	274	280	breast
O	280	281	-
O	281	291	conserving
O	292	299	surgery
O	300	301	(
O	301	304	BCS
O	304	305	)
O	306	309	for
B-eligibility	310	314	node
I-eligibility	314	315	-
I-eligibility	315	323	negative
I-eligibility	324	330	breast
I-eligibility	331	337	cancer
O	338	340	in
O	341	342	a
O	343	353	randomized
O	354	364	controlled
O	365	370	trial
O	371	372	(
O	372	375	RCT
O	375	376	)
O	376	377	.

O	378	386	Formalin
O	386	387	-
O	387	392	fixed
O	393	401	paraffin
O	401	402	-
O	402	410	embedded
O	411	412	(
O	412	416	FFPE
O	416	417	)
O	418	423	tumor
O	424	430	blocks
O	431	435	were
O	436	445	available
O	446	448	on
B-total-participants	449	452	989
O	453	455	of
B-total-participants	456	460	1234
O	461	469	patients
O	470	478	enrolled
O	479	481	in
O	482	485	the
O	486	503	Hypofractionation
O	504	509	Whole
O	510	516	Breast
O	517	528	Irradiation
O	529	530	(
O	530	534	HWBI
O	534	535	)
O	536	541	Trial
O	541	542	.

O	543	544	A
O	545	552	central
O	553	562	pathology
O	563	569	review
O	570	573	and
O	574	584	assessment
O	585	587	of
O	588	593	tumor
O	594	599	grade
O	600	605	using
O	606	609	the
O	610	620	Nottingham
O	621	628	grading
O	629	635	system
O	636	639	was
O	640	647	carried
O	648	651	out
O	651	652	.

O	653	659	Tumors
O	660	664	were
O	665	675	classified
O	676	678	by
O	679	688	molecular
O	689	696	subtype
O	697	699	as
O	700	707	luminal
O	708	709	A
O	709	710	,
O	711	718	luminal
O	719	720	B
O	720	721	,
O	722	726	HER2
O	727	735	enriched
O	735	736	,
O	737	742	basal
O	742	743	-
O	743	747	like
O	748	750	or
O	751	763	unclassified
O	764	769	using
O	770	771	a
O	772	775	six
O	775	776	-
O	776	785	biomarker
O	786	791	panel
O	791	792	;
O	793	795	ER
O	795	796	,
O	797	799	PR
O	799	800	,
O	801	804	HER
O	804	805	-
O	805	806	2
O	806	807	,
O	808	812	Ki67
O	812	813	,
O	814	817	CK5
O	817	818	/
O	818	819	6
O	820	823	and
O	824	828	EGFR
O	828	829	.

O	830	836	Tumors
O	837	841	were
O	842	846	also
O	847	857	classified
O	858	860	as
O	861	868	hypoxic
O	869	874	based
O	875	877	on
O	878	881	the
O	882	892	expression
O	893	895	of
O	896	900	HIF1
O	900	901	Î
O	901	902	±
O	902	903	,
O	904	908	CAIX
O	909	911	or
O	912	916	GLUT
O	916	917	-
O	917	918	1
O	918	919	.

O	920	923	The
O	924	931	primary
O	932	935	end
O	936	941	point
O	942	945	was
B-outcome-Measure	946	951	local
I-outcome-Measure	952	962	recurrence
I-outcome-Measure	963	964	(
I-outcome-Measure	964	966	LR
I-outcome-Measure	966	967	)
O	967	968	.

O	969	975	Median
O	976	982	follow
O	982	983	-
O	983	985	up
O	986	989	was
O	990	992	12
O	993	998	years
O	998	999	.

O	1000	1002	In
O	1003	1006	the
O	1007	1020	multivariable
O	1021	1024	Cox
O	1025	1030	model
O	1030	1031	,
O	1032	1041	molecular
O	1042	1049	subtype
O	1050	1053	was
O	1054	1057	the
O	1058	1062	only
O	1063	1069	factor
O	1070	1080	predictive
O	1081	1083	of
O	1084	1086	LR
O	1086	1087	,
O	1088	1091	the
B-outcome	1092	1094	10
I-outcome	1094	1095	-
I-outcome	1095	1099	year
I-outcome	1100	1110	cumulative
I-outcome	1111	1120	incidence
O	1121	1124	was
B-iv-bin-percent	1125	1126	4
I-iv-bin-percent	1126	1127	.
I-iv-bin-percent	1127	1128	5
I-iv-bin-percent	1128	1129	%
O	1130	1133	for
B-outcome	1134	1141	luminal
I-outcome	1142	1143	A
I-outcome	1144	1147	and
I-outcome	1148	1153	basal
I-outcome	1153	1154	-
I-outcome	1154	1158	like
O	1158	1159	,
B-iv-bin-percent	1160	1161	7
I-iv-bin-percent	1161	1162	.
I-iv-bin-percent	1162	1163	9
I-iv-bin-percent	1163	1164	%
O	1165	1168	for
B-outcome	1169	1176	luminal
I-outcome	1177	1178	B
O	1179	1182	and
B-iv-bin-percent	1183	1185	16
I-iv-bin-percent	1185	1186	.
I-iv-bin-percent	1186	1187	9
I-iv-bin-percent	1187	1188	%
O	1189	1192	for
B-outcome	1193	1196	HER
I-outcome	1196	1197	-
I-outcome	1197	1198	2
I-outcome	1199	1207	enriched
I-outcome	1208	1214	tumors
O	1215	1216	(
O	1216	1217	P
O	1218	1219	<
O	1220	1221	0
O	1221	1222	.
O	1222	1224	01
O	1224	1225	)
O	1225	1226	.

O	1227	1232	Tumor
O	1233	1238	grade
O	1238	1239	,
O	1240	1249	molecular
O	1250	1257	subtype
O	1258	1260	or
O	1261	1268	hypoxia
O	1269	1272	did
O	1273	1276	not
O	1277	1284	predict
O	1285	1293	response
O	1294	1296	to
O	1297	1314	hypofractionation
O	1314	1315	.

O	1316	1318	In
O	1319	1324	women
O	1325	1333	enrolled
O	1334	1336	in
O	1337	1340	the
O	1341	1345	HWBI
O	1346	1351	trial
O	1352	1361	following
O	1362	1365	BCS
O	1366	1371	tumor
O	1372	1381	molecular
O	1382	1389	subtype
O	1390	1399	predicted
O	1400	1402	LR
O	1402	1403	.

O	1404	1411	However
O	1412	1417	tumor
O	1418	1423	grade
O	1423	1424	,
O	1425	1434	molecular
O	1435	1442	subtype
O	1443	1446	and
O	1447	1454	hypoxia
O	1455	1458	did
O	1459	1462	not
O	1463	1470	predict
O	1471	1479	response
O	1480	1482	to
O	1483	1500	hypofractionation
O	1501	1511	suggesting
O	1512	1516	that
O	1517	1525	patients
O	1526	1530	with
O	1531	1535	node
O	1535	1536	-
O	1536	1544	negative
O	1545	1551	breast
O	1552	1558	tumors
O	1559	1561	of
O	1562	1565	all
O	1566	1572	grades
O	1573	1576	and
O	1577	1586	molecular
O	1587	1595	subtypes
O	1596	1599	may
O	1600	1602	be
O	1603	1609	safely
O	1610	1617	treated
O	1618	1622	with
O	1623	1639	hypofractionated
O	1640	1642	RT
O	1643	1651	regimens
O	1651	1652	.
